News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
RA CAPITAL MANAGEMENT, L.P.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 33.7% stake in VOR BIOPHARMA INC. |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 16.7% stake in 89BIO, INC. |
| 08/09/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DICE THERAPEUTICS, INC. |
| 07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/12/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Satsuma Pharmaceuticals, Inc. |
| 05/30/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 12.5% stake in Icosavax, Inc. |
| 04/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/10/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 18% stake in Werewolf Therapeutics, Inc. |
| 12/30/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/23/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 7.3% stake in ACHILLES THERAPEUTICS PLC |
| 12/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/09/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/05/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 17.6% stake in SOLID BIOSCIENCES INC. |
| 11/14/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/19/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/14/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in FORMA THERAPEUTICS HOLDING, INC. |
| 10/04/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 11% stake in SOLID BIOSCIENCES INC. |
| 09/26/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in POINT BIOPHARMA GLOBAL INC. |
| 09/16/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 8.6% stake in POINT BIOPHARMA GLOBAL INC. |
| 09/06/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 11% stake in SOLID BIOSCIENCES INC. |
| 09/02/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 18.9% stake in FORMA THERAPEUTICS HOLDING, INC. |
| 08/29/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.9% stake in POINT BIOPHARMA GLOBAL INC. |
| 08/12/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 14.6% stake in Werewolf Therapeutics, Inc. |
| 07/06/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/23/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/31/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 8.5% stake in Kala Pharmaceuticals, Inc. |
| 05/25/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/02/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 16.2% stake in Nkarta, Inc. |
| 04/01/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 15% stake in Kala Pharmaceuticals, Inc. |
| 03/14/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in Cytek BioSciences, Inc. |
|
|
|